Loading
What changed between revision 1 and revision 3, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/methuselah-foundation.md — the filesystem corpus, unchanged. Not an edit.
10.5 kB
Revision 1
Revision 3
lines 7–14 → 7–146 unchanged lines not shown
categories: ["organizations", "longevity"]categories: ["organizations", "longevity"]tags: ["aging", "prizes", "nonprofit", "tissue engineering", "organ preservation", "research funding"]tags: ["aging", "prizes", "nonprofit", "tissue engineering", "organ preservation", "research funding"]summary: "A Virginia nonprofit founded in the early 2000s that used prize competitions to seed research on life extension, regenerative medicine and organ engineering."summary: "A Virginia nonprofit founded in the early 2000s that used prize competitions to seed research on life extension, regenerative medicine and organ engineering."updated: "2026-07-27"updated: "2026-10-29"issues: ["The Thiel donation and the New Organ Liver Prize sums are stated without a source."]issues: ["The New Organ Liver Prize sum is given only as an order of magnitude and carries no source."]------ ```infobox```infoboxlines 30–67 → 30–6715 unchanged lines not shown
## Overview## Overview The foundation's method is deliberate: identify a bottleneck, define a measurable target, and offer money for hitting it rather than for proposing to try. Prizes shift the risk from funder to competitor, attract entrants a grant committee would not select, and produce a public benchmark. They also work only where the target is unambiguous, which has constrained what the foundation could take on.The foundation's method is deliberate. It identifies a bottleneck, defines a measurable target, and offers money for hitting the target rather than for proposing to try. Prizes shift the risk from funder to competitor, attract entrants a grant committee would not select, and produce a public benchmark. They work only where the target is unambiguous, however, and that has constrained what the foundation could take on. Its second function has been convening. For most of the 2000s, when aging research attracted little private money, the foundation was one of very few places where researchers, donors and advocates in the field met at all, and a substantial share of the modern longevity ecosystem traces to those connections.Its second function has been convening. For most of the 2000s, when aging research attracted little private money, the foundation was one of very few places where researchers, donors and advocates in the field met at all, and a substantial share of the modern longevity field traces back to those connections. ## The Mprize## The Mprize The Methuselah Mouse Prize, launched in 2003 and usually shortened to the Mprize, is the organization's signature programme. It awarded money in two categories, and the distinction between them was the point.The Methuselah Mouse Prize, launched in 2003 and usually shortened to the Mprize, is the organization's signature programme. It awarded money in two categories, and the distinction between them was central to its design. The **longevity** prize went to the oldest mouse ever recorded, by any means. Andrzej Bartke won it in 2003 with a growth-hormone-receptor-deficient dwarf mouse that lived beyond 1,800 days; his group's report of the underlying strain remains one of the largest proportional lifespan extensions recorded in a mammal.[^bartke2001]The **longevity** prize went to the oldest mouse ever recorded, by any means. Andrzej Bartke won it in 2003 with a growth-hormone-receptor-deficient dwarf mouse that lived beyond 1,800 days; his group's report of the underlying strain remains one of the largest proportional lifespan extensions recorded in a mammal.[^bartke2001] The **rejuvenation** prize was the more interesting design. It required the intervention to begin in middle age, which excludes developmental manipulations and lifelong regimens and demands that something be done to an already-aged animal. Stephen Spindler won it in 2004 with late-onset [[caloric-restriction]].The **rejuvenation** prize had the more interesting design. It required the intervention to begin in middle age, which excludes developmental manipulations and lifelong regimens and demands that something be done to an already-aged animal. Stephen Spindler won it in 2004 with late-onset [[caloric-restriction]]. > [!key] Why late-onset mattered> [!key] Why late-onset mattered> A drug that must be given from birth is not a medicine anyone can take. By paying only for interventions started after middle age, the rejuvenation prize enforced the constraint that separates a laboratory result from a possible therapy, and it did so a decade before the field generally adopted it. Nearly every intervention now taken seriously in aging biology is assessed on late-onset dosing.> A drug that must be given from birth is not a medicine anyone can take. By paying only for interventions started after middle age, the rejuvenation prize enforced the constraint that separates a laboratory result from a possible therapy, and it did so a decade before the field generally adopted it. Nearly every intervention now taken seriously in aging biology is assessed on late-onset dosing. The Mprize's leaderboard was never displaced by a wide margin, which is itself a finding. Two decades of work on mouse longevity has not produced an intervention that dramatically exceeds what dwarf mutants and caloric restriction achieved, and the strongest pharmacological signal in the field — [[rapamycin]] fed to genetically heterogeneous mice starting in late life, in the National Institute on Aging's Interventions Testing Program — produced extensions measured in percentages rather than multiples.[^harrison2009]The Mprize's leaderboard was never displaced by a wide margin, which is itself a finding. Two decades of work on mouse longevity have not produced an intervention that dramatically exceeds what dwarf mutants and caloric restriction achieved. The strongest pharmacological signal in the field, [[rapamycin]] fed to genetically heterogeneous mice starting in late life in the National Institute on Aging's Interventions Testing Program, produced extensions measured in percentages rather than multiples.[^harrison2009] ## The New Organ prizes## The New Organ prizes From 2014 the foundation extended the prize model to regenerative medicine under the New Organ banner, motivated by the [[organ-shortage]] arithmetic: transplant waiting lists are limited by donor supply, and no amount of surgical improvement changes that.From 2014 the foundation extended the prize model to regenerative medicine under the New Organ banner, motivated by the arithmetic of the [[organ-shortage]]. Transplant waiting lists are limited by donor supply, and no amount of surgical improvement changes that. The New Organ Liver Prize offered a seven-figure award for a bioengineered liver that could sustain a large animal for a defined period. It went unclaimed, which is an accurate reflection of where [[organ-bioprinting]] and [[tissue-engineering]] stand: vascularization at scale remains unsolved, and no whole solid organ has been grown and successfully transplanted.The New Organ Liver Prize offered a seven-figure award for a bioengineered liver that could sustain a large animal for a defined period. No winner has been announced, which accurately reflects where [[organ-bioprinting]] and [[tissue-engineering]] stand. Vascularization at scale remains unsolved, and no whole solid organ has been grown and successfully transplanted. The foundation also partnered with NASA on the Vascular Tissue Challenge, a competition to produce thick, metabolically functional vascularized human tissue that survives in the laboratory for a month. That prize was awarded in 2021 to a team from Wake Forest, and it is the clearest demonstration that a well-specified target in this area can be met.The foundation also partnered with NASA on the Vascular Tissue Challenge, run through its New Organ Alliance under NASA's Centennial Challenges programme. The challenge offered a $500,000 purse for teams producing vascularized human tissue more than a centimetre thick that keeps at least 85 percent of its cells alive through a 30-day trial. In June 2021 two teams from the Wake Forest Institute for Regenerative Medicine took first and second place with bioprinted liver tissue.[^nasa2021] The result is the clearest demonstration that a well-specified target in this area can be met. A related programme, the Organ Preservation Alliance, worked on extending the viability window for donated organs — the problem that [[cryonics|vitrification]] and normothermic perfusion research addresses, and one where progress has real near-term clinical value regardless of what one believes about life extension.A related programme, the Organ Preservation Alliance, worked on extending the viability window for donated organs. That is the problem [[cryonics|vitrification]] and normothermic perfusion research address, and progress on it has real near-term clinical value regardless of what one believes about life extension. ```timeline```timeline[[ { "year": "2003", "title": "Mprize launched", "text": "Two prizes are announced: one for the longest-lived mouse, one for the greatest late-onset extension, the latter designed to reward rejuvenation rather than slowed development." }, { "year": "2003", "title": "Mprize launched", "text": "Two prizes are announced: one for the longest-lived mouse, one for the greatest late-onset extension, the latter designed to reward rejuvenation rather than slowed development." }, { "year": "2003–2004", "title": "First winners", "text": "Andrzej Bartke wins the longevity category with a dwarf mouse living beyond 1,800 days; Stephen Spindler wins the rejuvenation category with late-onset caloric restriction." }, { "year": "2003-2004", "title": "First winners", "text": "Andrzej Bartke wins the longevity category with a dwarf mouse living beyond 1,800 days; Stephen Spindler wins the rejuvenation category with late-onset caloric restriction." }, { "year": "2006", "title": "Major donation", "text": "Peter Thiel commits several million dollars, one of the first large private gifts to life-extension research and a signal to other technology donors." }, { "year": "2006", "title": "Major donation", "text": "Peter Thiel pledges $3.5 million, combining direct funding with a matching challenge: one of the first large private gifts to life-extension research and a signal to other technology donors." }, { "year": "2009", "title": "SENS spun out", "text": "The damage-repair research programme is separated into an independent organization, SENS Research Foundation." }, { "year": "2009", "title": "SENS spun out", "text": "The damage-repair research programme is separated into an independent organization, SENS Research Foundation." }, { "year": "2014", "title": "New Organ", "text": "Prize competitions are extended to bioengineered organs and to organ preservation." }, { "year": "2014", "title": "New Organ", "text": "Prize competitions are extended to bioengineered organs and to organ preservation." }, { "year": "2021", "title": "Vascular Tissue Challenge awarded", "text": "A team from Wake Forest wins the NASA competition run in partnership with the foundation, producing thick vascularized tissue that survives for a month." } { "year": "2021", "title": "Vascular Tissue Challenge awarded", "text": "A team from Wake Forest wins the NASA competition run in partnership with the foundation, producing thick vascularized tissue that survives for a month." }lines 70–92 → 70–922 unchanged lines not shown
## Funding## Funding The foundation is philanthropically funded, and its most consequential single gift was from Peter Thiel in 2006 — several million dollars at a time when almost no private capital of that size was directed at aging. The gift mattered less for its amount than for its signalling effect on other technology donors, and much of the money that later founded [[calico]], [[altos-labs]] and [[retro-biosciences]] came from the same social network.The foundation is philanthropically funded. Its most consequential single gift came from Peter Thiel in 2006, at a time when almost no private capital of that size was directed at aging: a pledge of $3.5 million, made up of $500,000 in direct funding for pilot SENS projects over three years plus a 50-cent match for every donated dollar up to $3 million.[^fightaging2006] The pledge mattered less for its amount than for its signalling effect on other technology donors, and much of the money that later founded [[calico]], [[altos-labs]] and [[retro-biosciences]] came from the same social network. The organization later established the Methuselah Fund, a venture vehicle that invests in early-stage longevity and regenerative medicine companies, on the reasoning that some of the field's bottlenecks are commercial rather than scientific and that a nonprofit prize cannot address them.The organization later established the Methuselah Fund, a venture vehicle that invests in early-stage longevity and regenerative medicine companies, on the reasoning that some of the field's bottlenecks are commercial rather than scientific and that a nonprofit prize cannot address them. As of 2026 the foundation's own site presents its work as seven themed strategies, among them replacement parts, waste clearance and vascular restoration, with the Fund as the investment vehicle and the Mprize described among its early awards.[^mfoundation2026] ## Reception## Reception The foundation has attracted less criticism than most organizations in the field, largely because prizes make weaker claims than research programmes do. A prize does not assert that a result is achievable; it offers money if someone achieves it.The foundation has attracted less criticism than most organizations in the field, largely because prizes make weaker claims than research programmes do. A prize offers money if someone achieves a result without asserting that the result is achievable. The substantive criticism is about proportion. The sums involved are small — hundreds of thousands to low millions of dollars — relative to the cost of the work being incentivized, and the prizes have generally been won by researchers who were already doing the work rather than attracting new entrants. The Mprize's most-cited effect was reputational: it gave mouse longevity research a public scoreboard and made the field legible to donors.The substantive criticism is about proportion. The sums involved, hundreds of thousands to low millions of dollars, are small relative to the cost of the work being incentivized, and the prizes have generally been won by researchers who were already doing the work rather than by new entrants. The Mprize's most-cited effect was reputational: it gave mouse longevity research a public scoreboard and made the field legible to donors. A second criticism concerns the mission statement. "Make 90 the new 50 by 2030" is not a testable proposition, has no operational definition in terms of [[healthspan]] or function, and as of 2026 no route to meeting it on that timeline has been described. The foundation has continued to use it, which its critics read as the same rhetorical looseness that characterizes the [[longevity-escape-velocity]] literature more generally.A second criticism concerns the mission statement. "Make 90 the new 50 by 2030" is not a testable proposition and has no operational definition in terms of [[healthspan]] or function, and as of 2026 no route to meeting it on that timeline has been described. The foundation still states it as its overarching goal.[^mfoundation2026] Critics read this as the same rhetorical looseness that characterizes the [[longevity-escape-velocity]] literature more generally. ## Legacy## Legacy Methuselah's importance is as an origin point. It funded de Grey's early work, including the period in which he assembled the damage-repair framework later set out in *Ending Aging*,[^degrey2007] then spun out the organization that carried it, seeded the donor relationships that made large-scale private longevity funding possible, and demonstrated that prizes could operate in biology where they had previously been used mainly in aerospace — a lesson [[xprize-healthspan]] applied two decades later at far larger scale.Methuselah matters chiefly as an origin point. It funded de Grey's early work, including the period in which he assembled the damage-repair framework later set out in *Ending Aging*,[^degrey2007] and then spun out the organization that carried it. It seeded the donor relationships that made large-scale private longevity funding possible. It also demonstrated that prizes could operate in biology, where they had previously been used mainly in aerospace, a lesson [[xprize-healthspan]] applied two decades later at far larger scale. What it did not do is produce a therapy, which is the correct standard by which to judge a research funder and the one on which the entire field, not just this organization, has so far failed. The open question for the prize model in biology is whether the endpoints that matter can be specified precisely enough to compete over. A mouse's age is unambiguous. Restored human function is not, and every attempt to define it — including the current one — has had to invent its own measures.It did not produce a therapy. That is the correct standard by which to judge a research funder, and by it the entire field, not just this organization, has so far failed. The open question for the prize model in biology is whether the endpoints that matter can be specified precisely enough to compete over. A mouse's age is unambiguous. Restored human function is not, and every attempt to define it, including the current one, has had to invent its own measures. ## See also## See also lines 104–107 → 104–11011 unchanged lines not shown
[^degrey2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007. {A popular exposition of the author's own research agenda; it sets out a programme rather than reporting results.}[^degrey2007]: `book` de Grey, A. and Rae, M. *Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime*. St. Martin's Press, 2007. {A popular exposition of the author's own research agenda; it sets out a programme rather than reporting results.}[^bartke2001]: `paper` Bartke, A. et al. "Extending the lifespan of long-lived mice." *Nature*, 2001. {The record rests on a germline dwarfing mutation present from birth, which is the case the prize's separate rejuvenation category was written to exclude.}[^bartke2001]: `paper` Bartke, A. et al. "Extending the lifespan of long-lived mice." *Nature*, 2001. {The record rests on a germline dwarfing mutation present from birth, which is the case the prize's separate rejuvenation category was written to exclude.}[^harrison2009]: `paper` Harrison, D.E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." *Nature*, 2009. {Run at three independent sites on genetically heterogeneous mice, with dosing begun in late life; the gain is a percentage of median lifespan.}[^harrison2009]: `paper` Harrison, D.E. et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." *Nature*, 2009. {Run at three independent sites on genetically heterogeneous mice, with dosing begun in late life; the gain is a percentage of median lifespan.}[^fightaging2006]: `news` "Peter Thiel Gives Us All a $6 Million Challenge." *Fight Aging!*, September 2006. {An advocacy blog reproducing the pledge's press-release terms: $500,000 over three years plus up to $3 million in matching funds through 2009. It records the commitment, not what was ultimately disbursed.}[^nasa2021]: `statement` NASA. "Vascular Tissue Challenge (2016–2021)." Centennial Challenges, nasa.gov. {NASA co-ran the competition it describes; the page records the challenge rules, the $500,000 purse, and the June 2021 award to two Wake Forest Institute for Regenerative Medicine teams.}[^mfoundation2026]: `statement` Methuselah Foundation. "What We Do." mfoundation.org, accessed August 2026. {The foundation's own description of its current strategies, mission statement and vehicles; it records what the organization says about itself, not an independent assessment.} removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
87 lines are the same in both revisions, and 34 of them are not shown. Neither revision here is necessarily the current article — read Methuselah Foundation for the text this wiki stands behind today.